Compound Buyer is the independent UK guide to the research-peptide market, written for the people buying in it. We review who is selling and how well, explain how the market really works, and help buyers navigate it without getting burned, from spotting a scam to reading a certificate of analysis. No advertising, no affiliate fees, no exceptions.
A long-form regulatory map. How the MHRA, Border Force, Trading Standards, the National Crime Agency, the General Pharmaceutical Council, the ASA and Companies House are responding to a surge in illicit prescription-only injectable supply. The offences, the agencies, the policy direction, and where the legal line falls for sellers, intermediaries and end-users.
Read the feature →
A sceptical read of the BPC-157 literature in 2026. What the preclinical research describes, where the human evidence is missing, and what an honest research-peptide buyer should take from the published record.
Read the feature →
Where most UK-fronted wholesalers actually source from, why drop-shipping behind a British website is the largest hidden problem in the channel, and the three routes that pass the test. One rule overrides everything: no escrow, no recommendation.
Read the feature →
Our cover essay, and the piece we send to readers who write in asking where to start. The five things we have found, after several months of supplier correspondence, that actually separate a serious peptide company from a presentable one.
Read the guide →
A year in regulation, supply, the GLP-1 spillover and the new molecules. What changed in the British research-peptide market in 2025, and what to watch in 2026.
Read the feature →
What the term actually means, how the compounds are supplied and stored, and why purity testing matters.
What a good CoA contains, how to spot a reused one, and how to verify it independently.
What lab accreditation actually guarantees, and how to check a peptide testing lab in the UK.
The legal framework behind every UK peptide page, and the roles of MHRA, ASA and Trading Standards.
A short Thursday letter from the desk: supplier checks that did not warrant a full piece, regulatory notes worth flagging, and the occasional correction. No tracking, no sponsors, free to read.